Literature DB >> 7399622

Dopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension.

R Kolloch, K Kobayashi, V DeQuattro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7399622     DOI： 10.1161/01.hyp.2.4.390

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  12 in total

1.  Differential action of two prolactin isoforms on ischemia and re-perfusion-induced arrhythmias in rats in vivo.

Authors:  T F Krzeminski; K Mitrega; M Porc; M Zorniak; F Ryszka; Z Ostrowska; B Kos-Kudła
Journal:  J Endocrinol Invest       Date:  2010-10-04       Impact factor: 4.256

2.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

3.  Role of dopamine in the regulation of aldosterone and 18-hydroxycorticosterone secretion in man.

Authors:  J R Sowers; F W Beck
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

4.  Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Authors:  G Bise; C Foletti; C Beretta-Piccoli; P Weidmann; W H Ziegler; R Mordasini; C Bachmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

6.  Maternal and fetal prolactin in pregnancy-induced hypertension.

Authors:  M G Marlettini; A Cassani; A M Morselli-Labate; S Crippa; A Contarini; R Miniero; L Platè; C Orlandi
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

7.  Bromocriptine in the treatment of hypertension.

Authors:  R J Walden; J Hernandez; P Bhattacharjee; B Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?

Authors:  M Mannelli; M L De Feo; M Maggi; A Salvetti; G Giusti; M Serio
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.

Authors:  R M Carey; R M Stote; J W Dubb; L H Townsend; C E Rose; D L Kaiser
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.